| Business Summary | | Vical
Incorporated
develops
biopharmaceutical
products
based
on
its
patented
naked
DNA
gene
transfer
technologies
for
the
prevention
and
treatment
of
life-threatening
diseases.
The
Company
focuses
its
development
on
cancer
therapies
designed
to
induce
an
immune
response
against
cancer
cells
without
causing
serious
side
effects.
The
Company
has
retained
all
rights
to
its
internally
developed
cancer
product
candidates.
Its
lead
immunotherapy
product
candidate,
Allovectin-7,
is
in
Phase
III
and
Phase
II
registration
trials
for
patients
with
advanced
metastatic
malignant
melanoma,
an
aggressive
form
of
skin
cancer,
and
in
a
Phase
II
clinical
trial
for
patients
with
cancer
of
the
head
and
neck.
Its
second
immunotherapy
product
candidate,
Leuvectin,
is
in
Phase
II
clinical
trials
for
patients
with
advanced
metastatic
kidney
cancer
and
for
high-risk
patients
with
locally
confined
prostate
cancer. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vical
Inc.
develops
biopharmaceutical
products
based
on
their
patented
naked
gene
transfer
technologies
for
the
prevention
and
treatment
of
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
total
revenues
rose
2%
to
$4.2
million.
Net
loss
before
account.
change
rose
56%
to
$5.3
million.
Revenues
reflect
higher
contract
revenues
from
the
Office
of
Naval
Research,
the
NIH
and
Pfizer.
Higher
losses
reflect
increased
personnel
related
and
business
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| R. Gordon Douglas, Jr., M.D., 67 Chairman | -- | -- | Vijay Samant, 48 Pres,
CEO, Director | -- | -- | Martha Demski, 48 CFO,
VP, Sec., Treasurer | $230K | $183K | Alan Dow, J.D., Ph.D. VP,
Gen. Counsel | -- | -- | Jon Norman, Ph.D., 52 VP
of Research | 230K | 335K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|